ClinicalTrials.gg
RecruitingNCT06418282GRANDEUpdated May 4, 2026

Clinical Study to Evaluate the Effectiveness and Health Economics of a Novel Portable Non-Pneumatic Active Compression Device (NPCD) for Lymphedema/Phlebolymphedema

An interventional study of Dayspring in Phlebolymphedema, Lymphedema and Chronic Venous Insufficiency, sponsored by Koya Medical, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by Koya Medical, Inc. · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started May 2024; still recruiting 2 years 5 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Study summary

An open-label, multi-center, prospective VA study to evaluate the effectiveness and health economics of a Novel Portable Non-Pneumatic Active Compression Device (NPCD) for lymphedema/phlebolymphedema

Read the detailed description

An open-label, multi-center, prospective VA study to evaluate the effectiveness and health economics of a Novel Portable Non-Pneumatic Active Compression Device (NPCD) for lymphedema/phlebolymphedema

02

Conditions studied

  • Phlebolymphedema
  • Lymphedema
  • Chronic Venous Insufficiency

Browse trials for

03

In context

Lymphedema

529 studies on the registry are indexed under Lymphedema; 131 are open to participants now.

This study's planned enrollment of 100 is above the median of 50 across 369 interventional studies indexed under Lymphedema.

Browse Lymphedema studies →

Lead sponsor

Koya Medical, Inc. is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females ≥ 18 years of age
  • Capable and willing to sign the and deemed capable of following the study protocol
  • Subjects must have a diagnosis of unilateral or bilateral lower extremity edema or lower extremity lymphedema/phlebolymphedema as a consequence of chronic venous insufficiency
  • Subjects who have medical clearance using diagnostic confirmation through venous duplex to rule out DVT and superficial/deep reflux

Exclusion criteria

Exclusion Criteria:

  • Inability or unwillingness to participate in all aspects of study protocol and/or inability to provide
  • Individuals with a history or presence of a systemic disorder or condition that could place the subject at increased risk from sequential compression therapy
  • Subjects must not have any diagnosed cognitive or physical impairment that would interfere with the use of the device
  • Non-ambulatory individuals
  • Female: > 34 (5'4", 200 lbs.)
  • Male: BMI > 34 (5'9", 230 lbs.)
  • (Max circumference at patella 58 cm; Max circumference at gluteal fold 75 cm)
  • Diagnosis of lipedema
  • Diagnosis of active or recurrent cancer (\< 3 months since completion of chemotherapy, radiation therapy or primary surgery for the cancer)
  • Diagnosis of acute infection (in the last four weeks)
  • Diagnosis of active/open wound/ulcer
  • Diagnosis of acute thrombophlebitis (in last 2 months)
  • Diagnosis of pulmonary embolism or deep vein thrombosis within the previous 6 months
  • Diagnosis of pulmonary edema
  • Diagnosis of congestive heart failure (uncontrolled/uncompensated)
  • Diagnosis of chronic kidney disease with acute renal failure
  • Diagnosis of epilepsy
  • Subjects with poorly controlled asthma
  • Any condition where increased venous and lymphatic return is undesirable
  • Women who are pregnant, planning a pregnancy or nursing at study entry
  • Participation in any clinical trial of an substance or device during the past 30 days
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Dayspring, Non-Pneumatic Active Compression Device (NPCD)

    The Dayspring, an Non-Pneumatic Active Compression Device (NPCD) Active Wearable Compression Device is an FDA cleared calibrated active gradient pressure compression garment that is segmental and programmable and applies controlled sequential pressure from the distal to proximal-end of the limb in a cyclic manner.

    Device: Dayspring

Interventions

  • DeviceDayspring

    NPCD

06

What researchers measure

Primary outcomes

  1. Cost comparison between NPCD and historical reference (as reflected by hospital/resource utilization related to adverse events)

    Cost comparison between NPCD and historical reference (as reflected by hospital/resource utilization related to adverse events)

    Time frame: 6 months

  2. Mobility (daily steps using a pedometer)

    Mobility (daily steps using a pedometer)

    Time frame: 6 months

  3. Venous Clinical Severity Score (VCSS)

    Venous Clinical Severity Score (VCSS)

    Time frame: 180 days

Secondary outcomes

  1. Lower extremity edema response (limb girth reduction)

    Lower extremity edema response (limb girth reduction)

    Time frame: 6 months

  2. Safety/Adverse Events

    As assessed by reported adverse events

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Glenn Jacobowitz
    New York, New York 10016, United States
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06418282
Lead sponsor
Koya Medical, Inc.
Responsible party
Sponsor
First posted
May 17, 2024
Start date
May 13, 2024
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
May 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion